<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Advances in Molecular Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Advances in Molecular Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Успехи молекулярной онкологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-805X</issn><issn publication-format="electronic">2413-3787</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">726</article-id><article-id pub-id-type="doi">10.17650/2313-805X-2024-11-4-8-22</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>REVIEW ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОБЗОРНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Mechanistic and epidemiological evidence on the relationship between microbiota, virome and carcinogenesis</article-title><trans-title-group xml:lang="ru"><trans-title>Механистические и эпидемиологические данные о роли микробиоты и вирома в канцерогенезе</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9710-8178</contrib-id><name-alternatives><name xml:lang="en"><surname>Yakubovskaya</surname><given-names>M. G.</given-names></name><name xml:lang="ru"><surname>Якубовская</surname><given-names>М. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Marianna Gennadievna Yakubovskaya</p><p>24 Kashirskoe Shosse, Moscow 115522</p><p>6 Miklukho-Maklaya St., Moscow 117198</p></bio><bio xml:lang="ru"><p>Марианна Геннадиевна Якубовская</p><p>115522 Москва, Каширское шоссе, 24</p><p>117198 Москва, ул. Миклухо-Маклая, 6</p></bio><email>mgyakubovskaya@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5082-9883</contrib-id><name-alternatives><name xml:lang="en"><surname>Fetisov</surname><given-names>T. I.</given-names></name><name xml:lang="ru"><surname>Фетисов</surname><given-names>Т. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, Moscow 115522</p><p>6 Miklukho-Maklaya St., Moscow 117198</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p><p>117198 Москва, ул. Миклухо-Маклая, 6</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4443-8376</contrib-id><name-alternatives><name xml:lang="en"><surname>Solenova</surname><given-names>L. G.</given-names></name><name xml:lang="ru"><surname>Соленова</surname><given-names>Л. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, Moscow 115522</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4224-6303</contrib-id><name-alternatives><name xml:lang="en"><surname>Ryzhova</surname><given-names>N. I.</given-names></name><name xml:lang="ru"><surname>Рыжова</surname><given-names>Н. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, Moscow 115522</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8077-2307</contrib-id><name-alternatives><name xml:lang="en"><surname>Lokhonina</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Лохонина</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>6 Miklukho-Maklaya St., Moscow 117198</p></bio><bio xml:lang="ru"><p>117198 Москва, ул. Миклухо-Маклая, 6</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-3482-8954</contrib-id><name-alternatives><name xml:lang="en"><surname>Antonova</surname><given-names>I. A.</given-names></name><name xml:lang="ru"><surname>Антонова</surname><given-names>И. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, Moscow 115522</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3167-7204</contrib-id><name-alternatives><name xml:lang="en"><surname>Belitsky</surname><given-names>G. A.</given-names></name><name xml:lang="ru"><surname>Белицкий</surname><given-names>Г. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, Moscow 115522</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8599-6833</contrib-id><name-alternatives><name xml:lang="en"><surname>Kirsanov</surname><given-names>K. I.</given-names></name><name xml:lang="ru"><surname>Кирсанов</surname><given-names>К. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, Moscow 115522</p><p>6 Miklukho-Maklaya St., Moscow 117198</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p><p>117198 Москва, ул. Миклухо-Маклая, 6</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1787-2676</contrib-id><name-alternatives><name xml:lang="en"><surname>Aginova</surname><given-names>V. V.</given-names></name><name xml:lang="ru"><surname>Агинова</surname><given-names>В. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Viktoriya Viktorovna Aginova</p><p>24 Kashirskoe Shosse, Moscow 115522</p></bio><bio xml:lang="ru"><p>Виктория Викторовна Агинова</p><p>115522 Москва, Каширское шоссе, 24</p></bio><email>v.aginova@ronc.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Peoples’ Friendship University of Russia</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Российский университет дружбы народов»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-12-15" publication-format="electronic"><day>15</day><month>12</month><year>2024</year></pub-date><volume>11</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>8</fpage><lpage>22</lpage><history><date date-type="received" iso-8601-date="2024-12-09"><day>09</day><month>12</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-12-09"><day>09</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Yakubovskaya M.G., Fetisov T.I., Solenova L.G., Ryzhova N.I., Lokhonina A.V., Antonova I.A., Belitsky G.A., Kirsanov K.I., Aginova V.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, Якубовская М.Г., Фетисов Т.И., Соленова Л.Г., Рыжова Н.И., Лохонина А.В., Антонова И.А., Белицкий Г.А., Кирсанов К.И., Агинова В.В.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Yakubovskaya M.G., Fetisov T.I., Solenova L.G., Ryzhova N.I., Lokhonina A.V., Antonova I.A., Belitsky G.A., Kirsanov K.I., Aginova V.V.</copyright-holder><copyright-holder xml:lang="ru">Якубовская М.Г., Фетисов Т.И., Соленова Л.Г., Рыжова Н.И., Лохонина А.В., Антонова И.А., Белицкий Г.А., Кирсанов К.И., Агинова В.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://umo.abvpress.ru/jour/article/view/726">https://umo.abvpress.ru/jour/article/view/726</self-uri><abstract xml:lang="en"><p>Recent development of molecular and genetic technologies has demonstrated at the molecular level the co-evolutionary principles of interaction between microbiota, virome and the host organism, as well as the role of microorganisms and viruses both in maintaining physiological homeostasis and in the development of various diseases, including malignant neoplasms. The presented review is devoted to the analysis and generalization of modern data on microorganisms and viruses inhabiting the human body, their role in the processes of initiation, promotion and progression of carcinogenesis. The review provides information on known oncogenic viruses and microorganisms according to the modern classification of carcinogenic agents of the International Agency for Research on Cancer. Mechanistic data on the procarcinogenic effect of microbiota and virome are considered in accordance with the modern concept of key characteristics of a carcinogenic agent. Particular attention is paid to the analysis of data on the influence of microbiota and virome on the immunity of the host organism, including both the first results of immunotherapy with Coley toxin of soft tissue sarcomas and osteosarcomas, and data on the influence of individual types of microorganisms on the formation of the immunocompetent cell profile of the host organism. In addition, the influence of intratumor and intracellular microbiota, respectively, on the microenvironment of tumor cells and cellular signaling, including in solid tumors that have no contact with the external environment are also discussed. The data presented are important in terms of the holobiota concept, showing the interdependent existence of the human body, microorganisms and viruses, to improve the prevention and therapy of malignant neoplasms.</p></abstract><trans-abstract xml:lang="ru"><p>Развитие молекулярных и генетических технологий позволило на молекулярном уровне продемонстрировать коэволюционные принципы взаимодействия микробиоты, вирома и организма-хозяина, а также роль микроорганизмов и вирусов в поддержании физиологического гомеостаза и развитии различных заболеваний, включая злокачественные новообразования. представленный обзор посвящен анализу и обобщению современных данных о микроорганизмах и вирусах, населяющих человеческий организм, а также их роли в процессах инициации, промоции и прогрессии канцерогенеза. В статье приведена информация об известных онкогенных вирусах и микроорганизмах с учетом современной классификации канцерогенных агентов международного агентства по изучению рака (International Agency for Research on Cancer). Рассмотрены механистические данные о проканцерогенном воздействии микробиоты и вирома в соответствии с современной концепцией ключевых характеристик канцерогенного агента. Особое внимание уделено анализу данных о влиянии микробиоты и вирома на иммунитет организма-хозяина, включая первые результаты иммунотерапии токсином коли сарком мягких тканей и остеосарком, а также о воздействии отдельных видов микроорганизмов на формирование профиля зрелых иммунокомпетентных клеток организма-хозяина. кроме того, представлены сведения о влиянии внутриопухолевой и внутриклеточной микробиоты на микроокружение опухолевых клеток и клеточный сигналинг, в том числе в солидных опухолях, не имеющих контакта с внешней средой. приведенные данные важны в плане использования концепции холобиота, т. е. взаимозависимого существования организма человека, микроорганизмов и вирусов, для совершенствования профилактики и терапии злокачественных новообразований.</p></trans-abstract><kwd-group xml:lang="en"><kwd>microbiota</kwd><kwd>virome</kwd><kwd>dysbiosis</kwd><kwd>malignant neoplasm</kwd><kwd>carcinogenic hazard</kwd><kwd>key characteristic of a carcinogenic agent</kwd><kwd>antitumor immunity</kwd><kwd>tumor microenvironment</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>микробиота</kwd><kwd>вирус</kwd><kwd>дисбиоз</kwd><kwd>злокачественное новообразование</kwd><kwd>канцерогенная опасность</kwd><kwd>ключевая характеристика канцерогенного агента</kwd><kwd>противоопухолевый иммунитет</kwd><kwd>микроокружение опухоли</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The work was carried out with the financial support of the Russian Science Foundation (grant No. 23-65-00003).</funding-statement><funding-statement xml:lang="ru">Работа выполнена при финансовой поддержке Российского научного фонда (грант № 23-65-00003).</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Berg G., Rybakova D., Fischer D. et al. Microbiome definition re-visited: old concepts and new challenges. Microbiome 2020;30(8):103. DOI: 10.1186/s40168-020-00875-0</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Bassler B.L. Small talk: cell-to-cell communication in bacteria. Cell 2002;109(4):421–4. DOI: 10.1016/S0092-8674(02)00749-3</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Medzhitov R., Preston-Hurlburt P., Janeway C.A. Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997;388(6640):394–7. DOI: 10.1038/41131</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Thaiss C.A., Zmora N., Levy M., Elinav E. The microbiome and innate immunity. Nature 2016;535(7610):65–74. DOI: 10.1038/nature18847</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Silverstein A.M. Paul Ehrlich’s passion: the origins of his receptor immunology. Cell Immunol 1999;194(2):213–21. DOI: 10.1006/cimm.1999.1505</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Amarante-Mendes G.P., Adjemian S., Branco L.M. et al. Pattern recognition receptors and the host cell death molecular machinery. Front Immunol 2018;9:2379. DOI: 10.3389/fimmu.2018.02379</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Sender R., Fuchs S., Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol 2016;14(8):e1002533. DOI: 10.1371/journal.pbio.1002533</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Sepich-Poore G.D., Zitvogel L., Straussman R. et al. The icrobiome and human cancer. Science 2021;371(6536):eabc4552. DOI: 10.1126/science.abc4552</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Liang G., Bushman F.D. The human virome: assembly composition and host interactions. Nat Rev Microbiol 2021;19(8):514–27. DOI: 10.1038/s41579-021-00536-5</mixed-citation></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Belyavskaya V.A., Cherdyntseva N.V., Kzhyshkovska J.G., Litvyakov N.V. Microbiome, immune system and cancer: three sides of the one medal. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology 2022;21(6):131–44. (In Russ.). DOI: 10.21294/1814-4861-2022-21-6-131-144</mixed-citation><mixed-citation xml:lang="ru">Белявская В.А., Чердынцева Н.В., Кжышковска Ю.Г., Литвяков Н.В. Микробиом, иммунная система и рак: три стороны одной медали. Сибирский онкологический журнал 2022;21(6):131–44. DOI: 10.21294/1814-4861-2022-21-6-131-144</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Kaybysheva V.O., Zharova M.E., Filimendikova K.Yu. et al. Human microbiome: age-related changes and functions. Dokazatel’naya gastroenterologiya = Russian Journal of Evidence-based Gastroenterology 2020;9(2):42–55. (In Russ.). DOI: 10.17116/dokgastro2020902142</mixed-citation><mixed-citation xml:lang="ru">Кайбышева В.О., Жарова М.Е., Филимендикова К.Ю., Никонов Е.Л. Микробиом человека: возрастные изменения и функции. Доказательная гастроэнтерология 2020;9(2):42–55. DOI: 10.17116/dokgastro2020902142</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><mixed-citation>Mima K., Ogino S., Nakagawa S. et al. The role of intestinal bacteria in the development and progression of gastrointestinal tract neoplasms. Surg Oncol 2017;26(4):368. DOI: 10.1016/j.suronc.2017.07.011</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Chen J., Domingue J.C., Sears C.L. Microbiota dysbiosis in select human cancers: evidence of association and causality. Semin Immunol 2017;32:25–34. DOI: 10.1016/j.smim.2017.08.001</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Zitvogel L., Pietrocola F., Kroemer G. Nutrition, inflammation and cancer. Nat Immunol 2017;18(8):843–50. DOI: 10.1038/ni.3754</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Nejman D., Livyatan I., Fuks G. et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science 2020;368(6494):973–80. DOI: 10.1126/science.aay9189</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Samet J.M., Chiu W.A., Cogliano V. et al. The IARC monographs: updated procedures for modern and transparent evidence synthesis in cancer hazard identification. J Natl Cancer Inst 2019;112(1):30–7. DOI: 10.1093/jnci/djz169</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>De Martel C., Georges D., Bray F. et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health 2020;8(2):e180–90. DOI: 10.1016/S2214-109X(19)30488-7</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Biological agents. IARC Monographs on the evaluation of carcinogenic risks to humans. IARC, 2012. Vol. 100B. Available at: https://publications.iarc.fr/Book-And-Report-Series/Iarc-Monographs-On-The-Identification-Of-Carcinogenic-Hazards-To-Humans/Biological-Agents-2012.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Malaria and some polyomaviruses (SV40, BK, JC, and Markel cell viruses). IARC monographs on the working group on the evaluation of carcinogenic risks to humans. IARC, 2012. Vol. 104. Available at: https://publications.iarc.fr/Book-And-Report-Series/Iarc-Monographs-On-The-Identification-Of-Carcinogenic-Hazards-To-Humans/Malaria-And-Some-Polyomaviruses-SV40-BK-JC-And-Merkel-Cell-Viruses-2013.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Shannon-Lowe C., Rickinson A. The global landscape of EBV-associated tumors. Front Oncol 2019;9:713. DOI: 10.3389/fonc.2019.00713</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Wang Y., Yuan Y., Gu D. Hepatitis B and C virus Infections and the risk of biliary tract cancers: a meta-analysis of observational studies. Infect Agent Cancer 2022;17(1):45. DOI: 10.1186/s13027-022-00457-9</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Zhang W., Du F., Wang L. et al. Hepatitis virus-associated non-hodgkin lymphoma: pathogenesis and treatment strategies. J Clin Transl Hepatol 2023;11(5):1256–66. DOI: 10.14218/JCTH.2022.00079S</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Labo N., Whitby D. Kaposi’s sarcoma-associated herpesvirus: epidemiology and clinical features of related cancer. In: Viruses and human cancer. Ed. by S.D. Hudnall. NY: Springer, 2014. Pp. 323–340.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Silverberg M.J., Lau B., Achenbach C.J. et al. Cumulative incidence of cancer among HIV-infected individuals in North America. Ann Intern Med 2015;163(7):507–18. DOI: 10.7326/M14-2768</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Taberna M., Mena M., Pavón M.A. et al. Human papillomavirus-related oropharyngeal cancer. Ann Oncol 2017;28(10):2386–98. DOI: 10.1093/annonc/mdx304</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Van Dyne E.A., Henley S.J., Saraiya M. et al. Trends in human papillomavirus-associated cancers – United States, 1999–2015. MMWR Morb Mortal Wkly Rep 2018;67(33):918–24. DOI: 10.15585/mmwr.mm6733a2</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Whiteman D.C., Parma P., Fahey P. et al. Association of Helicobacter Pylori infection with reduced risk for esophageal cancer is independent of environmental and genetic modifiers. Gastroenterology 2010;139(1):73–83. DOI: 10.1053/j.gastro.2010.04.009</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Wyss K., Granath F., Wångdahl A. et al. Malaria and risk of lymphoid neoplasms and other cancer: a nationwide population-based cohort study. BMC Med 2020;18:296. DOI: 10.1186/s12916-020-01759-8</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Tan L.S.Y., Fredrik P., Ker L. et al. High-risk HPV genotypes and P16INK4a expression in a cohort of head and neck squamous cell carcinoma patients in singapore. Oncotarget 2016;7(52):86730–9. DOI: 10.18632/oncotarget.13502</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Dimitraki M.G., Sourvinos G. Merkel cell polyomavirus (MCPyV) and cancers: emergency bell or false alarm? Cancers (Basel) 2022,14(22):5548. DOI: 10.3390/cancers14225548</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Ceccarelli G., Giovanetti M., Sagnelli C. et al. Human immunodeficiency virus type 2: the neglected threat. Pathogens 2021;10(11):1377. DOI: 10.3390/pathogens10111377</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Si-Mohamed A., Badoual C., Hans S. et al. An unusual human papillomavirus type 82 detection in laryngeal squamous cell carcinoma: case report and review of literature. J Clin Virol 2012;54(2):190–3. DOI: 10.1016/j.jcv.2012.02.024</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Wallace J., Gonzalez H., Rajan R. et al. Anti-HIV drugs cause mitochondrial dysfunction in monocyte-derived macrophages. Antimicrob Agents Chemother 2022;66(4):e0194121. DOI: 10.1128/aac.01941-21</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Passerini S., Prezioso C., Prota A. et al. Detection of human neurotropic JCPyV DNA sequence in pediatric anaplastic xanthoastrocytoma. J Neurovirol 2023;29(2):232–6. DOI: 10.1007/s13365-023-01129-z</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Tavassoli N., Vojdani A., Salimi-Namin S. et al. Human BKV large T genome detection in prostate cancer and benign prostatic hyperplasia tissue samples by nested PCR: a case-control study. Mol Biol Res Commun 2023;12(4):149–54. DOI: 10.22099/mbrc.2023.47537.1836</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Starrett G.J., Buck C.B. BK Polyomavirus is a cause of bladder cancer. Curr Opin Virol 2019;39:8–15. DOI: 10.1016/j.coviro.2019.06.009</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Wong Y., Meehan M.T., Burrows S.R. et al. Estimating the global burden of Epstein–Barr virus-related cancers. J Cancer Res Clin Oncol 2022;148(1):31–46. DOI: 10.1007/s00432-021-03824-y</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Ibrahim Khalil A., Franceschi S., de Martel C. et al. Burden of Kaposi sarcoma according to HIV status: a systematic review and global analysis. Int J Cancer 2022;150(12):1948–57. DOI: 10.1002/ijc.33951</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Hernández-Ramírez R.U., Shiels M.S., Dubrow R., Engels E.A. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV 2017;4(11):e495–504. DOI: 10.1016/S2352-3018(17)30125-X</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Human immunodeficiency viruses and human T-cell lymphotropic viruses. IARC monographs on the evaluation of carcinogenic risks to humans. IARC, 2012. Vol. 67. Available at: https://publications.iarc.fr/Book-And-Report-Series/Iarc-Monographs-On-The-Identification-Of-Carcinogenic-Hazards-To-Humans/Human-Immunodeficiency-Viruses-And-Human-T-Cell-Lymphotropic-Viruses-1996.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Mirzaei R., Afaghi A., Babakhani S. et al. Role of microbiota-derived short-chain fatty acids in cancer development and prevention. Biomed Pharmacother 2021;139:111619. DOI: 10.1016/j.biopha.2021.111619</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Nougayrède J.-P., Homburg S., Taieb F. et al. Escherichia Coli induces DNA double-strand breaks in eukaryotic cells. Science 2006:313(5788):848–51. DOI: 10.1126/science.1127059</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Hartl K., Sigal M. Microbe-driven genotoxicity in gastrointestinal carcinogenesis. Int J Mol Sci 2020;21(20):7439. DOI: 10.3390/ijms21207439</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Jones R.M., Mercante J.W., Neish A.S. Reactive oxygen production induced by the gut microbiota: pharmacotherapeutic implications. Curr Med Chem 2012;19(10):1519–29. DOI: 10.2174/092986712799828283</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Tian X., Liu Z., Niu B. et al. E-cadherin/β-catenin complex and the epithelial barrier. J Biomed Biotechnol 2011;2011:567305. DOI: 10.1155/2011/567305</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Stein R.A., Riber L. Epigenetic effects of short-chain fatty acids from the large intestine on host cells. Microlife 2023;4. DOI: 10.1093/femsml/uqad032</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Dzutsev A., Badger J.H., Perez-Chanona E. et al. Microbes and cancer. Annu Rev Immunol 2017;35(1):199–228. DOI: 10.1146/annurev-immunol-051116-052133</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Turner L., Bitto N.J., Steer D.L. et al. Helicobacter pylori outer membrane vesicle size determines their mechanisms of host cell entry and protein content. Front Immunol 2018;9:1466. DOI: 10.3389/fimmu.2018.01466</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Shi Y., Meng L., Zhang C. Extracellular vesicles of Lacticaseibacillus paracasei PC-H1 induce colorectal cancer cells apoptosis via PDK1/AKT/Bcl-2 signaling pathway. Microbiol Res 2021;255:126921. DOI: 10.1016/j.micres.2021.126921</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Pistello M., Antonelli G. Integration of the viral genome into the host cell genome: a double-edged sword. Clin Microbiol Infect 2016;22(4):296–8. DOI: 10.1016/j.cmi.2016.01.022</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Spurgeon M.E., Liem A., Buehler D. et al. The Merkel cell polyomavirus T antigens function as tumor promoters in murine skin. Cancers (Basel) 2021;13(2):222. DOI: 10.3390/cancers13020222</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Read S.A., Douglas M.W. Virus induced inflammation and cancer development. Cancer Lett 2014;345(2):174–81. DOI: 10.1016/j.canlet.2013.07.030</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Nauts H.C., McLaren J.R. Coley toxins – the first century. Adv Exp Med Biol 1990;267:483–500. DOI: 10.1007/978-1-4684-5766-7_52</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Aghamajidi A., Maleki Vareki S. The effect of the gut microbiota on systemic and anti-tumor immunity and response to systemic therapy against cancer. Cancers (Basel) 2022;14(15):3563. DOI: 10.3390/cancers14153563</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Wang M., Yang G., Tian Y. et al. The role of the gut microbiota in gastric cancer: the immunoregulation and immunotherapy. Front Immunol 2023;14:1183331. DOI: 10.3389/fimmu.2023.1183331</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Ivanov I.I. Microbe hunting hits home. Cell Host Microbe 2017;21(3):282–5. DOI: 10.1016/j.chom.2017.02.010</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Jacouton E., Chain F., Sokol H. et al. Probiotic strain Lactobacillus casei BL23 prevents colitis-associated colorectal cancer. Front Immunol 2017;8:1553. DOI: 10.3389/fimmu.2017.01553</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Tarrah A., de Castilhos J., Rossi R.C. et al. In vitro probiotic potential and anti-cancer activity of newly isolated folate-producing Streptococcus thermophilus strains. Front Microbiol 2018;9:2214. DOI: 10.3389/fmicb.2018.02214</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Buret A.G., Motta J.P., Allain T. et al. Pathobiont release from dysbiotic gut microbiota biofilms in intestinal inflammatory diseases: a role for iron? J Biomed Sci 2019;26(1):1. DOI: 10.1186/s12929-018-0495-4</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Bordon Y. Microbiota: a viral understudy for commensal bacteria. Nat Rev Immunol 2015;15(1):4. DOI: 10.1038/nri3788</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Kernbauer E., Ding Y., Cadwell K. An enteric virus can replace the beneficial function of commensal bacteria. Nature 2014;516(7529):94–8. DOI: 10.1038/nature13960</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Champagne-Jorgensen K., Luong T., Darby T., Roach D.R. Immunogenicity of bacteriophages. Trends Microbiol 2023;31(10):1058–71. DOI: 10.1016/j.tim.2023.04.008</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>O’Neill L.A., Golenbock D., Bowie A.G. The history of Toll-like receptors – redefining innate immunity. Nat Rev Immunol 2013;13(6):453–60. DOI: 10.1038/nri3446</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>Jiang T., Zhou C., Ren S. Role of IL-2 in cancer immunotherapy. Oncoimmunology 2016;5(6):e1163462. DOI: 10.1080/2162402X.2016.1163462</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>Considine B., Hurwitz M.E. Current status and future directions of immunotherapy in renal cell carcinoma. Curr Oncol Rep 2019;21(4):34. DOI: 10.1007/s11912-019-0779-1</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>Rosenberg S.A., Yang J.C., Topalian S.L. et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994;30;271(12):907–13.</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>Smith M., García-Martínez E., Pitter M.R. et al. Trial watch: Toll-like receptor agonists in cancer immunotherapy. Oncoimmunology 2018;7(12):e1526250. DOI: 10.1080/2162402X.2018.1526250</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>Wu Z., Zhang S., Li L. et al. The gut microbiota modulates responses to anti-PD-1 and chemotherapy combination therapy and related adverse events in patients with advanced solid tumors. Front Oncol 2022;12:887383. DOI: 10.3389/fonc.2022.887383</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>Che S., Yan Z., Feng Y., Zhao H. Unveiling the intratumoral microbiota within cancer landscapes. iScience 2024;27(6):109893. DOI: 10.1016/j.isci.2024.109893</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>Zhang L., Yu L. The role of the microscopic world: exploring the role and potential of intratumoral microbiota in cancer immunotherapy. Medicine (Baltimore) 2024;103(20):e38078. DOI: 10.1097/MD.0000000000038078</mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation>Perry L.M., Cruz S.M., Kleber K.T. et al. Human soft tissue sarcomas harbor an intratumoral viral microbiome which is linked with natural killer cell infiltrate and prognosis. J Immunother Cancer 2023;11(1):e004285. DOI: 10.1136/jitc-2021-004285</mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation>Yang L., Li A., Wang Y., Zhang Y. Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy. Signal Transduct Target Ther 2023;8(1):35. DOI: 10.1038/s41392-022-01304-4</mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation>Wu J., Zhang P., Mei W., Zeng C. Intratumoral microbiota: implications for cancer onset, progression, and therapy. Front Immunol 2024;14:1301506. DOI: 10.3389/fimmu.2023.1301506</mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation>Xu J., Cheng M., Liu J. et al. Research progress on the impact of intratumoral microbiota on the immune microenvironment of malignant tumors and its role in immunotherapy. Front Immunol 2024;15:1389446. DOI: 10.3389/fimmu.2024.1389446</mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation>Rajasekaran K., Carey R.M., Lin X. et al. The microbiome of HPV-positive tonsil squamous cell carcinoma and neck metastasis. Oral Oncol 2021;117:105305. DOI: 10.1016/j.oraloncology.2021.105305</mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation>Chiba A., Bawaneh A., Velazquez C. et al. Neoadjuvant chemotherapy shifts breast tumor microbiota populations to regulate drug responsiveness and the development of metastasis. Mol Cancer Res 2020;18(1):130–9. DOI: 10.1158/1541-7786.MCR-19-0451</mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation>Chen G., Gao C., Jiang S. et al. Fusobacterium nucleatum outer membrane vesicles activate autophagy to promote oral cancer metastasis. J Adv Res 2024;56:167–79. DOI: 10.1016/j.jare.2023.04.002</mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation>Li L., Chandra V., McAllister F. Tumor-resident microbes: the new kids on the microenvironment block. Trends Cancer 2024;10(4):347–55. DOI: 10.1016/j.trecan.2023.12.002</mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation>Tiraboschi L., Braga D., Melacarne A. et al. Unveiling the impact of intratumoral microbiota in the treatment efficacy of soft tissue sarcoma. Cancer Res 2024;84(6):1277. DOI: 10.1158/1538-7445.AM2024-1277</mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation>Camacho E.M., Mesa-Pereira B., Medina C. et al. Engineering Salmonella as intracellular factory for effective killing of tumour cells. Sci Rep 2016:28(6):30591. DOI: 10.1038/srep30591</mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation>Groot A.J., Mengesha A., van der Wall E. et al. Functional antibodies produced by oncolytic clostridia. Biochem Biophys Res Commun 2007;364(4):985–9. DOI: 10.1016/j.bbrc.2007.10.126</mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation>Ribas A., Dummer R., Puzanov I. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and Improves anti-PD-1 immunotherapy. Cell 2017;170(6):1109–19.e10. DOI: 10.1016/j.cell.2017.08.027</mixed-citation></ref></ref-list></back></article>
